EUCTR2006-001473-24-IT进行中（未招募）不适用
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE - ND
Wyeth Pharmaceuticals Inc., Wyeth Research, Clinical Research and Development Division0 个研究点目标入组 56 人开始时间: 2007年3月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female hospitalized patients admitted to a neonatal intensive care unit NICU or special care nursery, at the time of enrollment. 2.Have a clinical indication for acid suppression to treat a presumptive diagnosis of GERD based on clinical symptoms suggestive of GERD and/or objective tests diagnostic of GERD. NOTE Disorders associated with or worsened by GERD, objective tests suggestive of GERD, and/or aspiration in conjunction with GERD should also be noted. These are considered supportive documentation of the clinical diagnosis 3.Be either term or post-term infants within the neonatal period 28 days , or be preterm infants with a corrected age of less than 44 weeks. 4.Have a body weight of at least 1500 grams. 5.Patients must be able to tolerate oral feeding and swallow the test article
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Cardiovascular instability, life-threatening arrhythmia, previous cardiopulmonary arrest, or mechanical ventilation.2. Known human immunodeficiency virus HIV or clinical manifestations of acquired immune deficiency syndrome AIDS or other significant immunodeficiency disorder or malignancy.3. Clinically significant laboratory test abnormality a. Aspartate aminotransferase AST or alanine aminotransferase ALT level 2 times upper limit of normal ULN .b. Alkaline phosphatase 2 times ULN age-corrected .4. Known history of positive serologic test for hepatitis B surface antigen HBsAg or hepatitis C virus HCV antibody or RNA.5. Known hypersensitivity to proton pump inhibitors PPIs , including pantoprazole.6. For PK Patients History of treatment with PPIs within 24 hours before the first 1st dose of test article.For PK/PD or PD Patients History of treatment with PPIs within 7 days before the first 1st dose of test article.7. For PK Patients Use of histamine-2-receptor antagonists H2RAs within 24 hours before the first 1st dose of test article. For PK/PD or PD Patients Use of H2RAs within 3 days before the first 1st dose of test article.8. Use of antacids within 2 hours before or after test article administration. Use of antacids is also prohibited 2 hours before or during pH-metry.9. Use of warfarin, carbamazepine, or phenytoin as well as rifampin for any disorder from at least 24 hours before the 1st dose of test article until after the final study procedure. 10.Significant renal or hepatic disease.
研究者
相似试验
进行中（未招募）
1 期
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC,CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASEDGRANULES ADMINISTERED AS A SUSPENSION IN NEONATES ANDPRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEALREFLUX DISEASEClinical diagnosis of gastroesophagal reflux disease (GERD) in neonates and preterm infantsEUCTR2006-001473-24-BEWyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.5
尚未招募
3 期
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC, CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASED GRANULES ADMINISTERED AS A SUSPENSION IN NEONATES AND PRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEAL REFLUX DISEASE10017969gastroesophageal refluxNL-OMON30569Wyeth4
进行中（未招募）
1 期
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC,CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASEDGRANULES ADMINISTERED AS A SUSPENSION IN NEONATES ANDPRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEALREFLUX DISEASEClinical diagnosis of gastroesophagal reflux disease (GERD) in neonates and preterm infantsEUCTR2006-001473-24-NLWyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.56
进行中（未招募）
1 期
A MULTICENTER, OPEN-LABEL PHARMACOKINETIC, PHARMACODYNAMIC,CLINICAL SYMPTOMS, AND SAFETY STUDY OF PANTOPRAZOLE DELAYED-RELEASEDGRANULES ADMINISTERED AS A SUSPENSION IN NEONATES ANDPRETERM INFANTS WITH A CLINICAL DIAGNOSIS OF GASTROESOPHAGEALREFLUX DISEASEClinical diagnosis of gastroesophagal reflux disease (GERD) in neonates and preterm infantsEUCTR2006-001473-24-FRWyeth Research, Clinical Research and Development, Division of Wyeth Pharmaceuticals Inc.90
进行中（未招募）
不适用
AN OPEN-LABEL, MULTICENTER, MULTIPLE-DOSE PHARMACOKINETIC AND 48-WEEK SAFETY AND EFFICACY TRIAL OF MARAVIROC IN COMBINATION WITH OPTIMIZED BACKGROUND THERAPY FOR THE TREATMENT OF ANTIRETROVIRAL-EXPERIENCED CCR5-TROPIC HIV-1 INFECTED CHILDREN 2-18 YEARS OF AGEEUCTR2008-006873-33-GBPfizer Inc, 235 East 42nd Street, New York, NY 10017125